INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer. Pavlakis N, Shitara K, Sjoquist K, Martin A, et al. J Clin Oncol 2024 Oct 4:JCO2400055. doi: 10.1200/JCO.24.00055.

Read + Share

Amedeo Smart

Independent Medical Education

Pavlakis N, Shitara K, Sjoquist K, Martin A, et al. INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer. J Clin Oncol 2024 Oct 4:JCO2400055. doi: 10.1200/JCO.24.00055.
PMID: 39365958